Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 20;14(1):9-20.
doi: 10.62347/WSNS5966. eCollection 2024.

Impact of chronic thrombocytopenia on healthcare resource utilization, in-hospital outcomes, and costs following percutaneous coronary intervention of chronic total occlusion: a nationwide propensity weighted analysis

Sheriff N Dodoo  1 , Bettye A Apenteng  2 , Alexis K Okoh  3 , Isaac A Opoku  4 , Ugochukwu O Egolum  5 , Nima Ghasemzadeh  6 , Ronnie Ramadan  6 , Glen Henry  6 , Gregory Giugliano  6
Affiliations

Impact of chronic thrombocytopenia on healthcare resource utilization, in-hospital outcomes, and costs following percutaneous coronary intervention of chronic total occlusion: a nationwide propensity weighted analysis

Sheriff N Dodoo et al. Am J Cardiovasc Dis. .

Abstract

Background: Data on the impact of chronic thrombocytopenia (CT) on outcomes following chronic total occlusion (CTO) percutaneous coronary interventions (PCI) is limited. Most studies are case reports and focused on postprocedural thrombocytopenia. The purpose of this present study is to assess the impact of CT (> one year) on health resource utilization (HRU), in-hospital outcomes, and cost following CTO PCI.

Methods: We used discharge data from the 2016-2018 National Inpatient Sample and propensity score-weighted approach to examine the association between CT and HRU among patients undergoing CTO PCI. HRU was measured as a binary indicator defined as a length of stay greater than seven days and/or discharge to a non-home setting. The cost was measured as total charges standardized to 2018 dollars. Both outcomes were assessed using generalized linear models adjusted for survey year, and baseline characteristics.

Results: Relative to its absence, the presence of CT following CTO PCI was associated with a 4.8% increased probability of high HRU (Population Average Treatment Effect (PATE) estimate = 0.048; 95% Confidence Interval (CI) = 0.041-0.055; P<0.001) and approximately $18,000 more in total hospital charges (PATE estimate = +$18,297.98; 95% CI = $15,101.33-$21,494.63, P<0.001).

Conclusion: Among chronic total occlusion patients undergoing percutaneous coronary intervention, those with chronic thrombocytopenia had higher resource use, including total hospital charges, and worse in-hospital outcomes when compared with those without chronic thrombocytopenia.

Keywords: Chronic total occlusion; healthcare resource utilization; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Study flowchart showing inclusion and exclusion criteria utilized in recruiting the study population. CTO, chronic total occlusion; CT, chronic thrombocytopenia; PCI, percutaneous coronary intervention; GLM, generalized linear model.
Figure 2
Figure 2
Forest plot illustrating the patient level and clinical factors that independently predicted HRU. Abbreviations: AKI, acute kidney injury; CTO, chronic total occlusion; DM, diabetes mellitus; HRU, High Resource utilization; PCI, percutaneous coronary intervention; PPM, permanent pacemaker. Data presented as mean + standard deviation, median (IQR), or n (%).
Figure 3
Figure 3
Forest plot illustrating the patient level and clinical factors that independently predicted total charges. Abbreviations: AKI, acute kidney injury; CTO, chronic total occlusion; DM, diabetes mellitus; HRU, high resource utilization; PCI, percutaneous coronary intervention; PPM, permanent pacemaker. Data presented as mean + standard deviation, median (IQR), or n (%).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94. - PubMed
    1. Aukrust P, Waehre T, Damås JK, Gullestad L, Solum NO. Inflammatory role of platelets in acute coronary syndromes. Heart. 2001;86:605–6. - PMC - PubMed
    1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–e228. - PubMed
    1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–e140. - PubMed
    1. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation. 2010;121:2575–83. - PubMed

LinkOut - more resources